{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Percentage of patients with prior EGFR failure assessed using RECIST whose cancer shrinks or disappears after treatment.","groups":[{"description":"Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.\n\nAll patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nPI3K inhibitor BKM120: Given PO\n\ncetuximab: Given IV","id":"OG000","title":"Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 28 days","title":"Response Rate in Patients With Prior EGFR Failure Assessed Using RECIST","type":"SECONDARY","unitOfMeasure":"Participants"}